Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 542 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo patch Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Smoking Environments on Craving and Smoking (CameraCue2.0)

NCT02551692
View directory record Official record
Conditions
Cigarette Smoking
Interventions
Nicotine Patch, Varenicline, Placebo Nicotine Patch, Placebo Capsule
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 60 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Skin Irritation Potential of PBI-100 Topical Cream in Healthy Participants

NCT04882631
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PBI-100 Topical Cream, Positive Control - Sodium laurel sulfate (SLS), PBI-100 Topical Cream, Vehicle, Negative Control
Drug · Other
Lead sponsor
Pyramid Biosciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Newtown Square, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine

NCT02420327
View directory record Official record
Conditions
Basic Science Study of the Mechanisms of Attentional Enhancement by Compounds Acting on the Nicotinic Receptor
Interventions
Placebo patch & placebo capsule, Placebo patch & galantamine capsule, Nicotine patch & placebo capsule, Nicotine patch and galantamine capsule
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 3 Interventional

HKT-500 in Adult Patients With Osteoarthritis (OA) Knee Pain

NCT00792727
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
ketoprofen Patch, Placebo Patch
Drug · Other
Lead sponsor
Hisamitsu Pharmaceutical Co., Inc.
Industry
Eligibility
45 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
36
States / cities
Birmingham, Alabama • Chandler, Arizona • Peoria, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 3 Interventional Results available

Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women

NCT00467259
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Testosterone Transdermal System, Placebo patch
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
45 Years to 70 Years · Female only
Enrollment
1,271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
115
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2011 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Early Phase 1 Interventional Results available

Oxytocin Effects on Cardiac Electrophysiology

NCT01780337
View directory record Official record
Conditions
Cardiac Arrhythmia
Interventions
Oxytocin, Saline
Drug · Other
Lead sponsor
William Whang
Other
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Not applicable Interventional Results available

Comparison of Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting

NCT00659737
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Aprepitant, Scopolamine
Drug
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 3 Interventional

HKT-500 in Adult Patients With Shoulder Pain

NCT00680472
View directory record Official record
Conditions
Pain
Interventions
HKT-500 Ketoprofen Topical Patch, Placebo Patch
Drug · Other
Lead sponsor
Hisamitsu Pharmaceutical Co., Inc.
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
35
States / cities
Birmingham, Alabama • Tempe, Arizona • Fullerton, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 4 Interventional Results available

Helping Those With Mental Illness Quit Smoking

NCT01783912
View directory record Official record
Conditions
Smoking, Nicotine Dependence, Mental Disorders
Interventions
Cognitive / Motivational Individual Sessions, Attention Control Individual Sessions, Nicotine Patch, Group Curriculum
Behavioral · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 99 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 18, 2026, 2:56 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

NCT05156281
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Remibrutinib, Teriflunomide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,007 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
50
States / cities
Phoenix, Arizona • Hanford, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 18, 2026, 2:56 AM EDT
Recruiting Phase 2 Interventional

Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants

NCT06206564
View directory record Official record
Conditions
Anal High-grade Squamous Intraepithelial Lesion, Anal HSIL, Anal HPV Infection, AIN
Interventions
Artesunate ointment, Placebo
Drug
Lead sponsor
Frantz Viral Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 3 Interventional

Etodolac-Lidocaine Patch in the Treatment of Acute Low Back Pain

NCT01968005
View directory record Official record
Conditions
Low Back Pain
Interventions
Etoreat®(Etodolac-Lidocaine Topical Patch), Placebo
Drug
Lead sponsor
MEDRx USA, Inc.
Industry
Eligibility
14 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
7
States / cities
Carlsbad, California • Miami, Florida • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 18, 2026, 2:56 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis

NCT04605094
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Benralizumab, Placebo / Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Los Angeles, California • Newport Beach, California • Bridgeport, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 3 Interventional

Diclofenac Patch for Treatment of Acute Pain Due to Mild to Moderate Soft Tissue Injuries (TAPED)

NCT00931866
View directory record Official record
Conditions
Acute Pain, Soft Tissue Injury
Interventions
Diclofenac Sodium, Matching Placebo Patch
Drug
Lead sponsor
Cerimon Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 3 Interventional Results available

Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)

NCT01569464
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
18
States / cities
Birmingham, Alabama • Jasper, Alabama • Gilbert, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2014 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 3 Interventional Results available

Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back Pain

NCT00490919
View directory record Official record
Conditions
Low Back Pain
Interventions
Buprenorphine transdermal system, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
86
States / cities
Anniston, Alabama • Mobile, Alabama • Chandler, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Lidocaine Patch 1.8% for Moderate to Severe Pain From Carpal Tunnel Syndrome

NCT04245371
View directory record Official record
Conditions
Carpal Tunnel Syndrome
Interventions
Lidocaine 1.8%, Placebo
Drug
Lead sponsor
John Papakonstantinou, MD
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rochester Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 18, 2026, 2:56 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Role of Menopause in Thermoregulation

NCT06798571
View directory record Official record
Conditions
Menopause, Aging
Interventions
Elagolix Oral Tablet, Estradiol patch, cellulose placebo, placebo patch
Drug · Other
Lead sponsor
Penn State University
Other
Eligibility
42 Years to 64 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis

NCT01962987
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Diclofenac sodium, Placebo
Drug · Other
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
31
States / cities
Fremont, California • Long Beach, California • Newport Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Not applicable Interventional

Testosterone Replacement in Postmenopausal Women With Stress Urinary Incontinence

NCT03116087
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
Testosterone patch, Placebo
Drug
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
45 Years to 75 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GTR in Comparison to Copaxone®

NCT01489254
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Glatiramer Acetate (GTR), Glatiramer Acetate (Copaxone®), Placebo
Drug
Lead sponsor
Synthon BV
Industry
Eligibility
18 Years to 55 Years
Enrollment
794 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
7
States / cities
Irvine, California • Port Charlotte, Florida • Sunrise, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 18, 2026, 2:56 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Preemptive Use of the Nicotine Patch for Postoperative Pain Relief After Open Abdominal Surgery

NCT00790829
View directory record Official record
Conditions
Postoperative Pain
Interventions
transdermal nicotine patch
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 18, 2026, 2:56 AM EDT
Terminated Phase 2 Interventional Results available

Treatment With Lorcaserin for Cocaine Use: The TLC Study

NCT03192995
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
lorcaserin, Placebo Oral Tablet, Substance use counseling, ACASI, Cocaine metabolites, Ecological Momentary Assessment (EMA), Balloon Analogue Risk Task (BART), Qualitative Exit Interview
Drug · Behavioral · Diagnostic Test
Lead sponsor
Glenn-Milo Santos
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 18, 2026, 2:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating the Absorption Of Varenicline Through The Skin Following Once Daily Application Of A Patch For 14 Days

NCT01234142
View directory record Official record
Conditions
Smoking Cessation
Interventions
varenicline free base patch, placebo patch
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2011 · Synced Oct 18, 2026, 2:56 AM EDT